Intravenous Infusions (XGHA:IIL) Accounts Receivable : GHS0.00 Mil (As of . 20)

View and export this data going back to 2015. Start your Free Trial

What is Intravenous Infusions Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Intravenous Infusions's accounts receivables for the quarter that ended in . 20 was GHS0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Intravenous Infusions's Net-Net Working Capital per share for the quarter that ended in . 20 was GHSN/A.

Intravenous Infusions Accounts Receivable Historical Data

The historical data trend for Intravenous Infusions's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intravenous Infusions Accounts Receivable Chart

Intravenous Infusions Annual Data

Trend

Accounts Receivable

Intravenous Infusions Semi-Annual Data

Accounts Receivable

Intravenous Infusions Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Intravenous Infusions Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Intravenous Infusions's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Intravenous Infusions's accounts receivable are only considered to be worth 75% of book value:

Intravenous Infusions's Net-Net Working Capital Per Share for the quarter that ended in . 20 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(	+	0.75 *	+	0.5 *	-	N/A
-		-	)	/	0
=	N/A

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Intravenous Infusions Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Intravenous Infusions's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Intravenous Infusions (XGHA:IIL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intravenous Infusions Ltd (XGHA:IIL) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA

Website

https://www.iil.com.gh

Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.